Taking people1. fázis
A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma
Key facts
- Where
- Badalona, Barcelona, Cáceres, Madrid, Málaga, Sabadell, Santander és Torrejón de Ardoz, SpanyolországSee the 8 sites
- Phase
- 1. fázis
Where in Spanyolország
- Institut Catala d'OncologiaBadalona, SpanyolországNo longer taking part
- Hospital Universitari Dexeus Grupo QuironsaludBarcelona, SpanyolországNo longer taking part
- Hospital San Pedro De AlcántaraCáceres, SpanyolországNo longer taking part
- Hospital Universitario 12 de OctubreMadrid, SpanyolországNo longer taking part
- Hospital Universitario Virgen de la VictoriaMálaga, SpanyolországNo longer taking part
- Parc Tauli Hospital UniversitariSabadell, SpanyolországNo longer taking part
- Hospital Universitario Marqués de ValdecillaSantander, SpanyolországNo longer taking part
- Hospital Universitario de TorrejonTorrejón de Ardoz, SpanyolországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Celltrion Inc.
- Trial code
- EU 2023-510017-26-00
- Record updated
- 2026. április 20.